Literature DB >> 15243101

Serotypes and genotypes of erythromycin-resistant group B streptococci in Korea.

Young Uh1, In Ho Jang, Gyu Yel Hwang, Mi Kyung Lee, Kap Jun Yoon, Hyo Youl Kim.   

Abstract

Among 78 erythromycin-resistant group B streptococcus (GBS) isolates from Korea, ermB was detected in 58 (74.4%), mefA was detected in 14 (17.9%), and ermTR was detected in 6 (7.7%). The most prevalent serotypes of erythromycin-resistant GBS were V (detected in 34 isolates [43.6%]) and III (detected in 33 isolates [42.3%]). All serotype V erythromycin-resistant GBS harbored the ermB gene.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15243101      PMCID： PMC446232          DOI： 10.1128/JCM.42.7.3306-3308.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  21 in total

1.  Emerging erythromycin resistance among group B streptococci in Korea.

Authors:  Y Uh; I H Jang; G Y Hwang; K J Yoon; W Song
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-01       Impact factor: 3.267

2.  Invasive disease due to group B streptococcal infection in adults: results from a Canadian, population-based, active laboratory surveillance study--1996. Sentinel Health Unit Surveillance System Site Coordinators.

Authors:  G J Tyrrell; L D Senzilet; J S Spika; D A Kertesz; M Alagaratnam; M Lovgren; J A Talbot
Journal:  J Infect Dis       Date:  2000-06-29       Impact factor: 5.226

3.  Mechanisms of macrolide resistance in clinical group B streptococci isolated in France.

Authors:  F Fitoussi; C Loukil; I Gros; O Clermont; P Mariani; S Bonacorsi; I Le Thomas; D Deforche; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  Trends in serotypes and antimicrobial susceptibility of group B streptococci isolated in Korea.

Authors:  K Lee; J W Shin; Y Chong; H Mikamo
Journal:  J Infect Chemother       Date:  2000-06       Impact factor: 2.211

5.  Erythromycin resistance genes in group A streptococci in Finland. The Finnish Study Group for Antimicrobial Resistance.

Authors:  J Kataja; P Huovinen; M Skurnik; H Seppälä
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

6.  Group B streptococcal disease in nonpregnant adults.

Authors:  M M Farley
Journal:  Clin Infect Dis       Date:  2001-07-20       Impact factor: 9.079

7.  Serotyping and antimicrobial susceptibility of group B Streptococcus over an eight-year period in southern Taiwan.

Authors:  W C Ko; H C Lee; L R Wang; C T Lee; A J Liu; J J Wu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-05       Impact factor: 3.267

8.  Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada.

Authors:  J C de Azavedo; M McGavin; C Duncan; D E Low; A McGeer
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

9.  Group B streptococci causing neonatal bloodstream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere.

Authors:  J I Andrews; D J Diekema; S K Hunter; P R Rhomberg; M A Pfaller; R N Jones; G V Doern
Journal:  Am J Obstet Gynecol       Date:  2000-10       Impact factor: 8.661

10.  Erythromycin and clindamycin resistance and telithromycin susceptibility in Streptococcus agalactiae.

Authors:  C Betriu; E Culebras; M Gómez; I Rodríguez-Avial; B A Sánchez; M C Agreda; J J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191
View more
  9 in total

1.  Heterogeneity of genotype-phenotype correlation among macrolide-resistant Streptococcus agalactiae isolates.

Authors:  Ulrich von Both; Anna Buerckstuemmer; Kirsten Fluegge; Reinhard Berner
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

2.  Dominance of serotype Ia among group B Streptococci causing invasive infections in nonpregnant adults in Portugal.

Authors:  E R Martins; J Melo-Cristino; M Ramirez
Journal:  J Clin Microbiol       Date:  2012-01-04       Impact factor: 5.948

3.  Group B streptococci causing neonatal infections in barcelona are a stable clonal population: 18-year surveillance.

Authors:  E R Martins; A Andreu; P Correia; T Juncosa; J Bosch; M Ramirez; J Melo-Cristino
Journal:  J Clin Microbiol       Date:  2011-06-22       Impact factor: 5.948

4.  Genotyping and Phylogenetic Analysis of Group B Streptococcus by Multiple Locus Variable Number Tandem Repeat Analysis in Iran.

Authors:  Farzaneh Khodaei; Behrooz Sadeghi Kalani; Naser Alizadeh; Alka Hassani; Mohammad Najafi; Enayatollah Kalantar; Abbas Amini; Mohammad Aghazadeh
Journal:  Galen Med J       Date:  2018-03-28

5.  Correlation of serotypes and genotypes of macrolide-resistant Streptococcus agalactiae.

Authors:  Young Uh; Hyo Youl Kim; In Ho Jang; Gyu Yel Hwang; Kap Jun Yoon
Journal:  Yonsei Med J       Date:  2005-08-31       Impact factor: 2.759

6.  Molecular epidemiology and distribution of serotypes, surface proteins, and antibiotic resistance among group B streptococci in Italy.

Authors:  Giovanni Gherardi; Monica Imperi; Lucilla Baldassarri; Marco Pataracchia; Giovanna Alfarone; Simona Recchia; Graziella Orefici; Giordano Dicuonzo; Roberta Creti
Journal:  J Clin Microbiol       Date:  2007-07-18       Impact factor: 5.948

7.  Association between capsular serotype V and macrolide resistance in group B Streptococcus.

Authors:  P Sendi; S Fröhlicher
Journal:  Epidemiol Infect       Date:  2014-06-05       Impact factor: 4.434

8.  Recent Epidemiological Changes in Group B Streptococcus Among Pregnant Korean Women.

Authors:  Seong Jin Choi; Jieun Kang; Young Uh
Journal:  Ann Lab Med       Date:  2021-07-01       Impact factor: 3.464

9.  Molecular Characteristic, Antibiotic Resistance, and Detection of Highly Immunoreactive Proteins of Group B Streptococcus Strains Isolated From Urinary Tract Infections in Polish Adults.

Authors:  Anna Dobrut; Dorota Ochońska; Ewa Brzozowska; Sabina Górska; Jolanta Kaszuba-Zwoinska; Monika Gołda-Cępa; Andrzej Gamian; Monika Brzychczy-Wloch
Journal:  Front Microbiol       Date:  2022-03-22       Impact factor: 5.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.